In a recent study published in the international journal Cell, scientists from Oxford University and other institutions identified a human antibody that could inhibit malaria parasites from entering blood cells. Related researchRead More…
Scientists, from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, reported that the ever-changing “head” of the flu virus protein has an unexpected Achilles’ heel. TheRead More…
Protein is an integral part of life. In cells, proteins combine to form large macromolecular complexes that cooperate with each other to perform specific functions. A large number of cancer studies haveRead More…
1. Nat Biotechnol: Edible antibody molecules contribute to the treatment of gastrointestinal diseases Therapeutic antibodies are increasingly used clinically to treat a variety of diseases. However, oral gut-targeted antibodies remain a challenge becauseRead More…
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by FDA, becoming the first targeted therapy for patients with NTRK gene fusion variant solid tumors. Loxo, on the other hand,Read More…
A new study identifies a single molecule as a key entry point for two dangerous bacteria to break through cell barriers and cause disease. The findings, published March 19 in the journalRead More…
Pharmaceutical giant and Company Eli Lilly Recently announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality (galcanezumab-gnlm) injection forRead More…
French pharmaceutical giant Sanofi recently announced that the key phase III clinical study ICARIA-MM to evaluate isatuximab in the treatment of recurrent/refractory multiple myeloma (R/R MM) has reached the main end point. TheRead More…
Kyowa Hakko Kirin announced submission of Crysvita (burosumab, KRN23) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of FGF-23-related hypophosphatemic rickets and osteomalacia. The active ingredient ofRead More…
Currently, the Scripps Research Institute has developed a new candidate AIDS vaccine that can effectively overcome the technical barriers of previous AIDS vaccines and stimulate powerful anti-HIV antibody responses in animal experiments.Read More…